NEWS

Vesalio Attains Key FDA Clinical Study Milestone

Nashville, TN, April 28, 2021, Vesalio announces it has accomplished a key FDA IDE study milestone to support entry into the US neurovascular market. Enrollment in the VITAL1 clinical trial, assessing the company’s NeVa VS™ technology in the treatment of symptomatic cerebral vasospasm following aneurysmal subarachnoid hemorrhage (aSAH), has been completed.

Perflow Medical Announces the First Clinical Use of the Cascade™ 17 Dyna...

NETANYA, Israel, March 10, 2021 /PRNewswire/ -- Perflow Medical, a private, Israeli-based innovator of solutions for neurovascular treatment, today announced it has launched to the European market the Cascade™ 17 Non-Occlusive Remodeling Net. 

Cerus Endovascular Receives FDA Breakthrough Device Designation for its...

FREMONT, Calif. and OXFORD, United Kingdom, Feb. 11, 2021 /PRNewswire/ -- Cerus Endovascular Ltd., a privately-held, commercial-stage medical device company, today announced that it has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its Contour Neurovascular System™.

Phenox GmbH expands with opening of new UK office.

Bochum, 10th February 2021. Despite a challenging year 2020, Phenox GmbH is pursuing its strategic plans in strengthening the footprint in key markets across Europe. As part of this strategy and in the light of Brexit, Phenox has taken the decision to open a UK entity materialising in its new office south of Birmingham.

Vesalio Receives Peripheral FDA 510k Clearance and Additional CE Approval

Nashville, TN, January 28, 2021 Vesalio reports it has obtained an FDA 510k clearance and its 4th CE approval.  The FDA 510k indication is for the removal of thrombi in peripheral blood vessels. The new CE approval expands the NeVa™ neuro-thrombectomy portfolio. Vesalio’s Drop ZoneTM technology, designed to remove the full spectrum of clots from vascular anatomy, has been acclaimed for consistently achieving high first-pass rates, a key parameter associated with better patient outcomes in stroke.

Lower-Profile Web Intrasaccular aneurysm treatment device receives FDA a...

Aliso Viejo, CA. – January 12, 2021 – MicroVention, Inc., a U.S.-based subsidiary of Terumo and a global neurovascular company, announced today the FDA Approval of the PMA Supplement for the WEB 17 System, a new addition to the WEB Aneurysm Embolization System for the treatment of intracranial wide neck bifurcation aneurysms. The WEB 17 System, designed with the latest microbraid technology, features a lower profile delivery system compatible with the VIA™ 17 microcatheter and includes additional device configurations.

Vesalio Reports 2,500 Patient Milestone

Nashville, TN, December 7, 2020 - Vesalio reports it has surpassed 2,500 clinical cases with the NeVa™ neuro-thrombectomy platform.  Physicians have evaluated the Neva Drop Zone™ technology with enthusiasm as it has shown a unique capability of removing the full spectrum of clot types in large vessel occlusion ischemic stroke. 

CERENOVUS Launches NIMBUS™ Geometric Clot Extractor to Remove Tough Clots

IRVINE, CA – October 7, 2020 – CERENOVUS, part of Johnson & Johnson Medical Devices Companies*, today announced the European launch of CERENOVUS NIMBUS™, designed to remove tough clots for successful revascularization in patients with acute ischemic stroke caused by a large vessel occlusion.

MicroVention-Terumo announces new leadership: the company appoints new P...

Aliso Viejo, CA. – September 22, 2020 –MicroVention, Inc., a U.S. based subsidiary of Terumo and leading global neurovascular company, announced today the appointment of a new President and CEO, Mr. Carsten Schroeder. The MicroVention acting President and CEO, Kazuaki Kitabatake, who has been in his role since August 2019, will continue as Chairman of the Board for MicroVention.  Mr. Schroeder will assume this position with MicroVention in early November 2020. 

Vesalio Expands Sales Network, Initiates Virtual Physician Training and...

Vesalio announces it has executed additional exclusive distribution agreements in Europe, Latin America, Asia, and the Middle East. With these new partnerships, the NeVa™ Thrombectomy System has gained market coverage in 53 countries.